An Effective Cell-penetrating Peptide-based Loading Method to Extracellular Vesicles and Enhancement in Cellular Delivery of Drugs

Overview

Journal Anal Bioanal Chem

Date 2025 Jan 21

PMID 39836222

Authors

Jin Zhang

Ning Su

Wei Liu

Mengran Li

Haoyang Zheng

Bing Li

Xue Jin

Mingxia Gao

Xiangmin Zhang

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs) have been demonstrated to own the advantages in evading phagocytosis, crossing biological barriers, and possessing excellent biocompatibility and intrinsic stability. Based on these characteristics, EVs have been used as effective therapeutic carriers for drug delivery, but the low drug loading capacity greatly limits further applications. Herein, we developed a drug loading method based on cell-penetrating peptide (CPP) to enhance the encapsulation of therapeutic reagents in EVs, and EVs-based drug delivery system achieved higher killing efficacy to tumor cells. Urinary EVs and chemotherapy reagent doxorubicin (DOX) were used as model. It is easy to conjugate CPP with DOX (CPP-DOX) through the linker N-succinimidyl 3-maleimidopropionate (SMP). CPP-DOX was incubated with EVs under a mild condition, promoting the encapsulation of DOX into EV cavities. CPP-DOX-EVs showed strong anticancer ability since EVs delivery facilitated the uptake by cancer cells. EVs loading of CPP-DOX exhibited higher drug loading efficiency at 37.18%, presenting about 2.5 times increase in efficiency over EVs loading of DOX through passive incubation. Easy operation and controllable condition further reinforce the advantages compared with other loading methods. CPP-based drug loading method provides an effective strategy for EVs-based drug delivery system.

References

Vargason A, Anselmo A, Mitragotri S . The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021; 5(9):951-967. DOI: 10.1038/s41551-021-00698-w. View

Park K . Controlled drug delivery systems: past forward and future back. J Control Release. 2014; 190:3-8. PMC: 4142099. DOI: 10.1016/j.jconrel.2014.03.054. View

Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I . Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023; 12(4). PMC: 9954613. DOI: 10.3390/cells12040659. View

Pisal D, Kosloski M, Balu-Iyer S . Delivery of therapeutic proteins. J Pharm Sci. 2010; 99(6):2557-75. PMC: 2857543. DOI: 10.1002/jps.22054. View

Lau J, Dunn M . Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2017; 26(10):2700-2707. DOI: 10.1016/j.bmc.2017.06.052. View

Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

Tenchov R, Bird R, Curtze A, Zhou Q . Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021; 15(11):16982-17015. DOI: 10.1021/acsnano.1c04996. View

Large D, Abdelmessih R, Fink E, Auguste D . Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021; 176:113851. DOI: 10.1016/j.addr.2021.113851. View

Zeng W, Wen Z, Chen H, Duan Y . Exosomes as Carriers for Drug Delivery in Cancer Therapy. Pharm Res. 2022; 40(4):873-887. DOI: 10.1007/s11095-022-03224-y. View

10.

Witwer K, Wolfram J . Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat Rev Mater. 2022; 6(2):103-106. PMC: 9481198. DOI: 10.1038/s41578-020-00277-6. View

11.

Tenchov R, Sasso J, Wang X, Liaw W, Chen C, Zhou Q . Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. ACS Nano. 2022; 16(11):17802-17846. PMC: 9706680. DOI: 10.1021/acsnano.2c08774. View

12.

Escude Martinez de Castilla P, Tong L, Huang C, Sofias A, Pastorin G, Chen X . Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. Adv Drug Deliv Rev. 2021; 175:113801. DOI: 10.1016/j.addr.2021.05.011. View

13.

Pirisinu M, Pham T, Zhang D, Hong T, Nguyen L, Le M . Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. Semin Cancer Biol. 2020; 80:340-355. DOI: 10.1016/j.semcancer.2020.08.007. View

14.

Li H, Xu W, Li F, Zeng R, Zhang X, Wang X . Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles. Drug Deliv. 2022; 29(1):192-202. PMC: 8741238. DOI: 10.1080/10717544.2021.2023697. View

15.

Wang K, Kumar U, Sadeghipour N, Massoud T, Paulmurugan R . A Microfluidics-Based Scalable Approach to Generate Extracellular Vesicles with Enhanced Therapeutic MicroRNA Loading for Intranasal Delivery to Mouse Glioblastomas. ACS Nano. 2021; 15(11):18327-18346. DOI: 10.1021/acsnano.1c07587. View

16.

Kimiz-Gebologlu I, Oncel S . Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022; 347:533-543. DOI: 10.1016/j.jconrel.2022.05.027. View

17.

Nguyen V, Kim H, Choi Y, Park J, Choi E . Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors . Drug Deliv. 2022; 29(1):2621-2631. PMC: 9367655. DOI: 10.1080/10717544.2022.2105444. View

18.

Liu L, Deng Q . Role of platelet-derived extracellular vesicles in traumatic brain injury-induced coagulopathy and inflammation. Neural Regen Res. 2022; 17(10):2102-2107. PMC: 9083154. DOI: 10.4103/1673-5374.335825. View

19.

Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K . Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015; 6:6716. PMC: 4396394. DOI: 10.1038/ncomms7716. View

20.

Ha D, Yang N, Nadithe V . Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016; 6(4):287-96. PMC: 4951582. DOI: 10.1016/j.apsb.2016.02.001. View